Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Echo Therapeutics Inc (OTCQB:ECTE)

Delayed Data
As of Aug 24
 -0.03 / -4.17%
Today’s Change
Today|||52-Week Range
Health Technology
Medical Specialties

Company Description

Echo Therapeutics is a medical device company develops non-invasive, wireless continuous glucose monitoring (CGM) system with potential use in the wearable-health consumer market and the diabetes outpatient market. The company is developing its Prelude SkinPrep System as a platform technology to allow for enhanced skin permeation that will enable two important applications: Analyte extraction, with the Symphony CGM System for needle-free, continuous glucose monitoring in critical patients as the first application and Needle-free drug delivery, with the delivery of lidocaine as the first application. Echo Therapeutics was founded on September 14, 2007 and is headquartered in Iselin, NJ.

Contact Information

Echo Therapeutics, Inc.
99 Wood Avenue South
Iselin New Jersey 08830-2734
P:(732) 201-4189
Investor Relations:



Other institutional9.26%
Individual stakeholders10.08%
Mutual fund holders1.84%

Top Executives

Scott Wayne HollanderPresident, Chief Executive Officer & Director
Thomas H. BishopVice President-Operations & Product Development
Alan Wayne SchoenbartChief Financial Officer & Secretary
Christine H. OlimpioDirector-Investor Relations & Communications